Vevo
Yasmin Sameni currently serves as the Head of Operations at Vevo Therapeutics since October 2022. Previously, Yasmin held the position of Business Operations Associate at Good Chemistry Company from April 2022 to September 2022, contributing to the innovative approach in materials discovery through computational and quantum chemistry. Yasmin's professional journey includes serving as Executive Business Partner at 1QBit from May 2021 to April 2022, along with experience at Lions Gate Law as Commissioner for Taking Affidavits and Executive Legal Assistant from 2015 to 2021. Educational qualifications include a Bachelor of Applied Science in Criminology and certificates in Legal Studies and Police Studies, all obtained from Simon Fraser University, complemented by a high school diploma from École Dr. Charles Best Secondary School.
This person is not in any teams
This person is not in any offices
Vevo
1 followers
Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.